{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:23:19Z","timestamp":1707524599178},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,11]]},"DOI":"10.7759\/cureus.26757","type":"journal-article","created":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T19:57:36Z","timestamp":1657569456000},"source":"Crossref","is-referenced-by-count":0,"title":["Advanced Case of Cardiac Amyloidosis Presents With Chronic Diarrhea"],"prefix":"10.7759","author":[{"given":"Mahmoud","family":"Abdelsamia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osama","family":"Mosalem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasser","family":"Radwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manal","family":"Boumegouas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Laird Fick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2020.1835263","article-title":"Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"27","author":"Benson MD","year":"2020","unstructured":"Benson MD, Buxbaum JN, Eisenberg DS, et al.. Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid. 2020, 27:217-22. 10.1080\/13506129.2020.1835263","journal-title":"Amyloid"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13169","article-title":"Systemic amyloidosis from A (AA) to T (ATTR): a review","volume":"289","author":"Muchtar E","year":"2021","unstructured":"Muchtar E, Dispenzieri A, Magen H, et al.. Systemic amyloidosis from A (AA) to T (ATTR): a review. J Intern Med. 2021, 289:268-92. 10.1111\/joim.13169","journal-title":"J Intern Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.08.041","article-title":"Incidence of AL amyloidosis in Olmsted County, Minnesota, 1990 through 2015","volume":"94","author":"Kyle RA","year":"2019","unstructured":"Kyle RA, Larson DR, Kurtin PJ, et al.. Incidence of AL amyloidosis in Olmsted County, Minnesota, 1990 through 2015. Mayo Clin Proc. 2019, 94:465-71. 10.1016\/j.mayocp.2018.08.041","journal-title":"Mayo Clin Proc"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.08.006","article-title":"A modern primer on light chain amyloidosis in 592 patients with mass spectrometry-verified typing","volume":"94","author":"Muchtar E","year":"2019","unstructured":"Muchtar E, Gertz MA, Kyle RA, et al.. A modern primer on light chain amyloidosis in 592 patients with mass spectrometry-verified typing. Mayo Clin Proc. 2019, 94:472-83. 10.1016\/j.mayocp.2018.08.006","journal-title":"Mayo Clin Proc"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbapap.2005.08.014","article-title":"Clinical aspects of systemic amyloid diseases","volume":"1753","author":"Obici L","year":"2005","unstructured":"Obici L, Perfetti V, Palladini G, Moratti R, Merlini G. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta. 2005, 1753:11-22. 10.1016\/j.bbapap.2005.08.014","journal-title":"Biochim Biophys Acta"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-001164","article-title":"Dangerous small B-cell clones","volume":"108","author":"Merlini G","year":"2006","unstructured":"Merlini G, Stone MJ. Dangerous small B-cell clones. Blood. 2006, 108:2520-30. 10.1182\/blood-2006-03-001164","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000126569.75419.74","article-title":"Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress","volume":"94","author":"Brenner DA","year":"2004","unstructured":"Brenner DA, Jain M, Pimentel DR, et al.. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res. 2004, 94:1008-10. 10.1161\/01.RES.0000126569.75419.74","journal-title":"Circ Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)89487-9","article-title":"Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only","volume":"100","author":"Skinner M","year":"1996","unstructured":"Skinner M, Anderson JJ, Simms R, et al.. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med. 1996, 100:290-8. 10.1016\/S0002-9343(97)89487-9","journal-title":"Am J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/s0025-6196(12)60634-x","article-title":"Symptomatic gastric Amyloidosis in patients with primary systemic amyloidosis","volume":"68","author":"Menke DM","year":"1993","unstructured":"Menke DM, Kyle RA, Fleming CR, Wolfe JT 3rd, Kurtin PJ, Oldenburg WA. Symptomatic gastric Amyloidosis in patients with primary systemic amyloidosis. Mayo Clin Proc. 1993, 68:763-7. 10.1016\/s0025-6196(12)60634-x","journal-title":"Mayo Clin Proc"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/00365520902783717","article-title":"Primary (AL) amyloidosis with gastrointestinal involvement","volume":"44","author":"Madsen LG","year":"2009","unstructured":"Madsen LG, Gimsing P, Schi\u00f8dt FV. Primary (AL) amyloidosis with gastrointestinal involvement. Scand J Gastroenterol. 2009, 44:708-11. 10.1080\/00365520902783717","journal-title":"Scand J Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-015-0250-0","article-title":"Light chain amyloidosis: patient experience survey from the Amyloidosis Research Consortium","volume":"32","author":"Lousada I","year":"2015","unstructured":"Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Light chain amyloidosis: patient experience survey from the Amyloidosis Research Consortium. Adv Ther. 2015, 32:920-8. 10.1007\/s12325-015-0250-0","journal-title":"Adv Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2009.126664","article-title":"Screening panels for detection of monoclonal gammopathies","volume":"55","author":"Katzmann JA","year":"2009","unstructured":"Katzmann JA, Kyle RA, Benson J, et al.. Screening panels for detection of monoclonal gammopathies. Clin Chem. 2009, 55:1517-22. 10.1373\/clinchem.2009.126664","journal-title":"Clin Chem"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00486-4","article-title":"Comprehensive review of AL amyloidosis: some practical recommendations","volume":"11","author":"Al Hamed R","year":"2021","unstructured":"Al Hamed R, Bazarbachi AH, Bazarbachi A, Malard F, Harousseau JL, Mohty M. Comprehensive review of AL amyloidosis: some practical recommendations. Blood Cancer J. 2021, 11:97. 10.1038\/s41408-021-00486-4","journal-title":"Blood Cancer J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-751628","article-title":"Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death","volume":"129","author":"Muchtar E","year":"2017","unstructured":"Muchtar E, Gertz MA, Kumar SK, et al.. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017, 129:2111-9. 10.1182\/blood-2016-11-751628","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-629790","article-title":"What is new in diagnosis and management of light chain amyloidosis?","volume":"128","author":"Palladini G","year":"2016","unstructured":"Palladini G, Merlini G. What is new in diagnosis and management of light chain amyloidosis?. Blood. 2016, 128:159-68. 10.1182\/blood-2016-01-629790","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25566","article-title":"Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis","volume":"94","author":"Sidana S","year":"2019","unstructured":"Sidana S, Sidiqi MH, Dispenzieri A, et al.. Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. Am J Hematol. 2019, 94:1020-6. 10.1002\/ajh.25566","journal-title":"Am J Hematol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.53","article-title":"Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center","volume":"48","author":"Dispenzieri A","year":"2013","unstructured":"Dispenzieri A, Seenithamby K, Lacy MQ, et al.. Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center. Bone Marrow Transplant. 2013, 48:1302-7. 10.1038\/bmt.2013.53","journal-title":"Bone Marrow Transplant"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis E","year":"2021","unstructured":"Kastritis E, Palladini G, Minnema MC, et al.. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021, 385:46-58. 10.1056\/NEJMoa2028631","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-771220","article-title":"A phase 1\/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis","volume":"130","author":"Sanchorawala V","year":"2017","unstructured":"Sanchorawala V, Palladini G, Kukreti V, et al.. A phase 1\/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017, 130:597-605. 10.1182\/blood-2017-03-771220","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-396903","article-title":"A phase 1\/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis","volume":"119","author":"Kastritis E","year":"2012","unstructured":"Kastritis E, Terpos E, Roussou M, et al.. A phase 1\/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood. 2012, 119:5384-90. 10.1182\/blood-2011-12-396903","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/104470-advanced-case-of-cardiac-amyloidosis-presents-with-chronic-diarrhea","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:38:44Z","timestamp":1707507524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/104470-advanced-case-of-cardiac-amyloidosis-presents-with-chronic-diarrhea"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,11]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.26757","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7,11]]}}}